[New Product] Beilupharma's Ioversol Injection Receives Approval

Recently, Beilupharma received the "Drug Registration Certificate" for its Ioversol Injection, approved and issued by the National Medical Products Administration (NMPA).

The original innovator of Ioversol Injection is the U.S. company Mallinckrodt. Its indications include: (1) Coronary angiography and left ventriculography, aortography, and peripheral and visceral angiography in adults; (2) Contrast-enhanced CT scanning of the head and body, venography, and excretory urography in adults; (3) Cardiovascular angiography in children.

Ioversol Injection was approved as a Category 4 chemical drug, which is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs, further enriching the company's layout of iodine contrast agent products. In addition to Ioversol Injection, the company's iodine contrast agent product line also includes Iohexol Injection, Iodixanol Injection, Iopamidol Injection, Iomeprol Injection, Iopromide Injection, etc.. The company's contrast agent product line has become more diversified, enhancing the market competitiveness of its contrast agent products. Beilupharma will actively carry out preparations for the launch of the new product and push it to the market as soon as possible.